Document is current
Any future updates will be listed below
-
Authors
Dib, Carla
Queenan, Jack A. https://orcid.org/0000-0003-1057-3892
Swartzrock, Leah https://orcid.org/0000-0003-0584-0896
Willner, Hana
Denis, Morgane https://orcid.org/0000-0002-9485-0131
Ahmed, Nouraiz
Moulana Zada, Fareha https://orcid.org/0009-0007-6676-3384
Borges, Beltran
Charlesworth, Carsten T.
Lum, Tony
Yates, Bradley P.
Kwon, Caleb Y.
Scorzo, Augustino V. https://orcid.org/0000-0001-5573-5985
Davis, Scott C.
Davis, Jessie R.
He, Ran
Xie, Jun https://orcid.org/0000-0001-9565-1567
Gao, Guangping https://orcid.org/0000-0003-0097-9012
MacKenzie, Tippi C.
Liu, David R. https://orcid.org/0000-0002-9943-7557
Newby, Gregory A. https://orcid.org/0000-0001-7869-2615
Czechowicz, Agnieszka D. https://orcid.org/0000-0003-2909-2669
- License Information
-
More Information
Article History
Received: 26 September 2024
Accepted: 10 June 2025
First Online: 31 July 2025
Competing interests
: A.C. discloses financial interests in the following entities working in the rare genetic disease space: Beam Therapeutics, Editas Medicines, Fulcrum Therapeutics, Global Blood Therapeutics, Inograft Biotherapeutics, Land Medicine, Prime Medicine, and Spotlight Therapeutics. D.R.L. is a consultant and/or equity holder of Prime Medicine, Beam Therapeutics, Pairwise Plants, and nChroma Bio, companies that use gene editing or genome engineering. J.R.D. is a current employee and equity holder of Prime Medicine. D.R.L. is an inventor of base editors (US 20170121693). D.R.L. and J.R.D. are inventors of AAV vectors encoding base editors (US 20250064981). A.C. and S.C.D. have a financial interest in GV, a venture capital firm funded by Alphabet, and its portfolio. A.C. has received research funding from Rocket Pharmaceuticals, Jasper Therapeutics and STRM.Bio. S.C.D. has received research funding from Aera Therapeutics. None of these entities funded or were involved in this study. The remaining authors report no competing interests.
